Ethics in clinical research.

Area of Science:

• Drug development and regulation
• Pharmaceutical industry impact on healthcare

Background:

• Pharmaceutical companies heavily fund new drug research and development.
• This financial investment can introduce bias, prioritizing market approval over true clinical value.

Purpose of the Study:

• To analyze how pharmaceutical industry R&D funding influences drug approval processes.
• To identify methodological flaws and regulatory loopholes that may compromise drug efficacy and safety evaluations.

Main Methods:

• Review of existing literature on drug development and regulatory frameworks.
• Analysis of common biases in clinical trial design, data reporting, and regulatory approval pathways.

Main Results:

• Methodological flaws such as biased study populations, inadequate comparators, surrogate endpoints, and selective publication inflate perceived drug value.
• Regulatory environments permit drugs with no added value, often favoring placebo comparisons or non-inferiority trials.
• This leads to market entry of drugs potentially less effective or safe than existing options, at higher costs.

Conclusions:

• Current regulations prioritize commercial interests over public health needs.
• Legislative and regulatory settings require reform to ensure drugs offer genuine therapeutic advancement and meet patient needs.